Stacy Lindborg
CIK 1813667 · President and CEO · last filed 2026-10-13
Stacy Lindborg is a President and CEO who has filed 35 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing shows the insider was granted $3.2K of IMNN on Oct 13, 2026. Across all open-market trades the lifetime net is +$44.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $143.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMNN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
997 LENOX DRIVE, SUITE 100
LAWRENCEVILLE, NJ 08648
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMNN | President and CEO | 116,952 | $1.23 | $143.9K | $24.5K | 23 | 2026-10-13 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Co-Chief Executive Officer | 48,229 | $0.75 | $36.1K | $20.4K | 8 | 2025-01-03 |
| Imunon, Inc. (CLSN) Delisted | Director | — | $1.96 | — | $0 | 3 | 2022-06-15 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-13 | IMNN | Grant (A) | +2,977 | $3.2K | EDGAR |
| 2026-09-28 | IMNN | Grant (A) | +6,697 | $9.4K | EDGAR |
| 2026-09-15 | IMNN | Grant (A) | +5,504 | $8.1K | EDGAR |
| 2026-09-01 | IMNN | Grant (A) | +6,822 | $10.9K | EDGAR |
| 2026-08-17 | IMNN | Grant (A) | +6,615 | $10.9K | EDGAR |
| 2026-08-04 | IMNN | Grant (A) | +5,010 | $8.0K | EDGAR |
| 2026-07-21 | IMNN | Grant (A) | +4,907 | $9.0K | EDGAR |
| 2026-07-07 | IMNN | Grant (A) | +2,534 | $4.8K | EDGAR |
| 2026-06-29 | IMNN | Grant (A) | +67,150 | $115.5K | EDGAR |
| 2026-06-23 | IMNN | Grant (A) | +1,803 | $3.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.